University of Glasgow

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update (2024) Gossec L, Kerschbaumer A, Ferreira RJ, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, et al. Journal article Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis (2024) Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, et al. Journal article Differentiating primary and secondary FSGS using non-invasive urine biomarkers. (2024) Catanese L, Siwy J, Wendt R, Amann KU, Beige J, Hendry B, Mischak H, et al. Journal article Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension (2024) Taylor RS, Bentley A, Metcalfe K, Lobo MD, Kirtane AJ, Azizi M, Clark C, et al. Journal article Microfabrication Technologies for Nanoinvasive and High-Resolution Magnetic Neuromodulation (2024) Ge C, Masalehdan T, Shojaei Baghini M, Duran Toro V, Signorelli L, Thomson H, Gregurec D, Heidari H Journal article, Review article Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial (2024) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty SD, et al. Journal article SegMorph: Concurrent Motion Estimation and Segmentation for Cardiac MRI Sequences (2024) Bi N, Zakeri A, Xia Y, Cheng N, Taylor ZA, Frangi AF, Gooya A Journal article Response of Blood Pressure to Renal Denervation Is Not Associated with Genetic Variants (2024) Delles C, Schmieder R, Daly R, Kannenkeril D, Bosch A, Lauder L, Kunz M, et al. Journal article Immune mechanisms of depression in rheumatoid arthritis (2023) Brock J, Basu N, Schlachetzki JC, Schett G, McInnes IB, Cavanagh J Journal article, Review article Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article